Stereotactic body radiotherapy as treatment for organ confined low and intermediate risk prostate carcinoma, a seven year study

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Katz, Alan ^a   Kang, Josephine ^a,b  

^a Flushing Radiation Oncology   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Prostate cancer; Stereotactic radiotherapy

Indexed keywords

AMIFOSTINE; BISACODYL; FLEET ENEMA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER RISK; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CYBERKNIFE; DISEASE CONTROL; FOLLOW UP; GASTROINTESTINAL DISEASE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; PROSTATE CARCINOMA; QUALITY OF LIFE; RADIATION DOSE; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; DISEASE FREE SURVIVAL; INTERMEDIATE RISK PATIENT; RISK FACTOR; SCORING SYSTEM;

EID: 84906565201     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00240     Document Type: Article

References (24)

1. Collins CD. 1991. Radical external beam radiotherapy for localized carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 3:358
2. Freeman DE, King CR. 2011. Stereotactic body radiotherapy for low-risk prostate cancer: fiveyear outcomes. Radiat Oncol 6:3
3. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, et al. 2012. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 118:3681-90
4. Kang JK, Cho CK, Choi CW, Yoo S, Kim MS, et al. 2011. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 97:43-8
5. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, et al. 2013. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 109:217-21
6. Katz AJ, Santoro M, Diblasio F, Ashley R. 2013. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 8:118
7. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. 2012. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. International journal of radiation oncology, biology, physics 82:e17-24
8. Dasu A, Toma-Dasu I. 2012. Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients. Acta Oncol 51:963-74
9. Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD. 2012. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organconfined prostate cancer. The American journal of managed care 18:e186-93
10. ASTRO. 2013. Stereotactic body radiation therapy: model policy.2
11. Network NCC. 2014. Guidelines for Prostate Cancer.
12. Romanelli P, Schaal DW, Adler JR. 2006. Image-guided radiosurgical ablation of intra- and extra-cranial lesions. Technology in cancer research & treatment 5:421-8
13. Simone NL, Menard C, Soule BP, Albert PS, Guion P, et al. 2008. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. International journal of radiation oncology, biology, physics 70:90-5
14. Roach M, 3rd, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, et al. 2006. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International journal of radiation oncology, biology, physics 65:965-74
15. Cox JD, Stetz J, Pajak TF. 1995. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International journal of radiation oncology, biology, physics 31:1341-6
16. Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, et al. 2004. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. International journal of radiation oncology, biology, physics 58:1048-55
17. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. 2005. High-dose-rate intensitymodulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. International journal of radiation oncology, biology, physics 61:1306-16
18. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. 2006. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. The Journal of urology 176:1415-9
19. Weller MA, Kupelian P, al e. 2013. Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer: Long-term Outcomes and a Comparison to Standard Dose- Escalated RT. International journal of radiation oncology, biology, physics 87:S152-S3
20. Stock RG, Klein TJ, Cesaretti JA, Stone NN. 2009. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. International journal of radiation oncology, biology, physics 74:753-8
21. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, et al. 2011. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29:2020-6
22. Kim DWN, Cho LC, Straka C, Christie A, Lotan Y, et al. 2014. Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer. International journal of radiation oncology, biology, physics 89:509-17
23. Zaorsky NG, Hurwitz MD, al e. 2013. Evaluation of Biologically Equivalent Dose Escalation, Clinical Outcome, and Toxicity in Prostate Cancer Radiation Therapy: A Meta-Analysis of 12,000 Patients. International journal of radiation oncology, biology, physics 87:S24
24. Katz A, Kang J. 2014. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol 9:1